A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP

Completed · Phase 1

Conditions studied: Pneumonia, Pneumocystis Carinii, HIV Infections

In brief

To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia (PCP) in AIDS patients TMTX is an experimental new drug which is effective for treatment of PCP, but has been given to only a few patients. Therefore it is not certain if TMTX is better, the same as, or not as effective as conventional drugs against PCP.

Key facts

Study ID

NCT00000998

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

50

Expected to finish

1989-04-01

Last updated by the study team

2021-11-04

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must:
• Have Pneumocystis carinii pneumonia (PCP) that has not been treated for current episode. PCP must be documented by observation of > 1 cluster of organisms in sputum, bronchial secretion, or lung tissue.
• Have clinical symptoms of respiratory disease or radiologic abnormalities.

You may not qualify if…

• Patient cannot have significant emotional disorder.
• Concurrent Medication: Excluded:
• Drugs likely to be bone marrow toxic.
• Investigational drugs.
• Prior Medication: Excluded:
• Three patients in each group cannot have had zidovudine (AZT) for at least 2 months prior to administration of trimetrexate.

Where it is running

• Los Angeles County - USC Med Ctr — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.